A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
暂无分享,去创建一个
Yusuke Nakamura | Chen Jiang | Kouros Owzar | Liewei Wang | Federico Innocenti | Howard L McLeod | Michiaki Kubo | Liang Li | Hitoshi Zembutsu | Richard L Schilsky | Patrick Evans | Mark J Ratain | Hedy L Kindler | Yusuke Nakamura | Liewei Wang | R. Schilsky | K. Owzar | M. Ratain | P. Friedman | T. Mushiroda | M. Kubo | K. Giacomini | H. McLeod | R. Goldberg | H. Hurwitz | D. Hollis | F. Innocenti | N. Cox | Liang Li | H. Zembutsu | P. Evans | H. Kindler | Dylan M Glubb | Kathleen M Giacomini | Herbert Hurwitz | Richard M Goldberg | Chen Jiang | Taisei Mushiroda | Donna Hollis | Dylan Glubb | Nancy L Cox | Paula Friedman | M. Kubo
[1] Chia-Hung Liu,et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization , 2006, Nucleic Acids Res..
[2] Kenneth Pienta,et al. APC/CTNNB1 (β‐catenin) pathway alterations in human prostate cancers , 2002 .
[3] A. González-Neira,et al. Multiple Genetic Loci Modulate Lung Adenocarcinoma Clinical Staging , 2011, Clinical Cancer Research.
[4] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[5] K. Cooney,et al. Genome‐wide linkage scan for prostate cancer susceptibility from the university of michigan prostate cancer genetics project: Suggestive evidence for linkage at 16q23 , 2009, The Prostate.
[6] A. Jemal,et al. Increase in Incidence of Colorectal Cancer Among Young Men and Women in the United States , 2009, Cancer Epidemiology Biomarkers & Prevention.
[7] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[8] Wei Zhang,et al. SCAN: SNP and copy number annotation , 2010, Bioinform..
[9] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[10] G. Morgan,et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. , 2007, Blood.
[11] A. Sood,et al. Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells , 2008, Clinical Cancer Research.
[12] M. Dolan,et al. The use of genomic information to optimize cancer chemotherapy. , 2011, Seminars in oncology.
[13] T. Tahara,et al. Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia. , 2007, International journal of molecular medicine.
[14] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Perez,et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Schilsky,et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Korc,et al. Pathways for aberrant angiogenesis in pancreatic cancer , 2003, Molecular Cancer.
[18] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[19] Bing-Zhong Xu,et al. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. , 2010, Cancer letters.
[20] M. Hartman,et al. Molecular epidemiology and its current clinical use in cancer management. , 2010, The Lancet. Oncology.
[21] Krishna R. Kalari,et al. Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers , 2009, PloS one.
[22] W. Scheithauer,et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Xiang,et al. Interleukin-17F Suppresses Hepatocarcinoma Cell Growth via Inhibition of Tumor Angiogenesis , 2010, Cancer investigation.
[24] R. Aqeilan,et al. WWOX: Its genomics, partners, and functions , 2009, Journal of cellular biochemistry.
[25] Yusuke Nakamura,et al. Japanese single nucleotide polymorphism database for 267 possible drug‐related genes , 2006, Cancer science.
[26] D. Pectasides,et al. Pancreatic cancer: current and future treatment strategies. , 2009, Cancer treatment reviews.
[27] M. Nishimura,et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. , 2006, The Journal of allergy and clinical immunology.
[28] T. Tahara,et al. The Influence of Polymorphisms of Interleukin-17A and Interleukin-17F Genes on the Susceptibility to Ulcerative Colitis , 2007, Journal of Clinical Immunology.
[29] G. Sledge,et al. Cutting Edge: IL-17F, a Novel Cytokine Selectively Expressed in Activated T Cells and Monocytes, Regulates Angiogenesis and Endothelial Cell Cytokine Production1 , 2001, The Journal of Immunology.
[30] K. Pienta,et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. , 2002, Genes, chromosomes & cancer.